Summary
Johnson & Johnson (JNJ) filed an 8-K on July 17, 2024, primarily to disclose its financial results for the second quarter ended June 30, 2024. The filing includes a press release and supplementary sales data, offering investors a look into the company's operational performance and financial condition during the period. Investors should review the attached exhibits for detailed sales figures and earnings statements to understand the company's revenue generation and profitability trends.
Key Highlights
- 1JNJ announced its second quarter 2024 sales and earnings on July 17, 2024.
- 2The 8-K filing's primary purpose is to report the company's financial performance for the quarter ended June 30, 2024.
- 3Key financial information is contained within the attached press release (Exhibit 99.1).
- 4Investors can find unaudited comparative supplementary sales data and condensed consolidated statements of earnings in Exhibit 99.2.
- 5The filing provides a snapshot of JNJ's financial condition and results of operations for the specified period.
- 6No other significant operational or strategic updates were detailed in this specific 8-K filing beyond the Q2 2024 financial results.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce and disclose Johnson & Johnson's sales and earnings results for the second quarter ended June 30, 2024.
The detailed financial results, including sales and earnings, are primarily available in the press release (Exhibit 99.1) and the unaudited comparative supplementary sales data and condensed consolidated statement of earnings (Exhibit 99.2) attached to this 8-K filing.
Based on the provided information, this 8-K filing is solely focused on reporting the second quarter 2024 financial results. It does not appear to contain details on new strategic initiatives or other significant business updates outside of the financial performance.
Johnson & Johnson announced these results on July 17, 2024, and the 8-K filing was made on the same date.